Resumen

ARUS SOLER, Enrique et al. Tratamiento de la hepatitis crónica C con interferón alfa 2b recombinante: Ensayo clínico controlado aleatorizado. Rev cubana med [online]. 2000, vol.39, n.1, pp. 12-20. ISSN 1561-302X.

A multicenter randomized controlled trial was conducted on 35 patients suffering from chronic hepatitis C. 19 of them were treated with interleukin (group I), whereas the other 16 made up the control group. Recombinant interleukin 2b alpha was used on a 9-month treatment scheme with doses that were gradually increased according to the biochemical response. A biochemical response of 57.9 % was obtained at the end of the treatment, while in the control group this response was of 12.5 %. The group of patients under treatment had a permanent biochemical response of 36.4 %. There was an improvement of the histological activity index of the study group, but in the control group this index was almost the same on the initial biopsy and the posttreatment biopsy. Tolerance to interleukin was good. It was concluded that the interleukin effect on the group of treated patinets was beneficial.

Palabras clave : HEPATITIS C, CHRONIC; RANDOMIZED CONTROLLED TRIALS; INTERFERONS..

        · resumen en Español     · texto en Español     · Español ( pdf )